Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer

被引：124

作者：

Okarvi, S. M. ^{[1
]}

机构：

[1] King Faisal Specialist Hosp & Res Ctr, Cyclotron & Radiopharmaceut Dept, Riyadh 11211, Saudi Arabia

来源：

CANCER TREATMENT REVIEWS | 2008年 / 34卷 / 01期

关键词：

radiolabeled peptides; tumor imaging; radiotherapy; somatostatin; bombesin; cytotoxic peptide;

D O I：

10.1016/j.ctrv.2007.07.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

A hope for the diagnosis and treatment of cancer is the development of new tumorspecific peptide-based radiopharmaceuticals. The overexpression of many peptide receptors on human tumors makes such receptors an attractive potential target for diagnostic imaging and radiotherapy with specifically designed radiolabeled peptides. The use of solid-phase peptide synthesis, and the availabitity of a wide range of bifunctional chelating agents for the convenient radiolabeling of bioactive peptides with different radionuclides have produced a wide variety of medicinally useful peptide radiopharmaceuticals. A few of these peptides, such as somatostatin, bombesin, cholecystokinin/gastrin, neurotensin and vasoactive intestinal peptide are currently under investigation for their possible clinical. applications in nuclear oncology. This article presents the recent development in radiolabeled small peptides, with major emphasis on somatostatin and bombesin analogs. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：13 / 26

页数：14

共 95 条

[1]

Somatostatin receptor scintigraphy with 99mTc-depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer:: A pilot study [J].